- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04513106
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
Promoting Advance Care Planning in Persons With Early Stage Dementia and Their Family Caregivers in the Community: a Feasibility Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to test the feasibility and preliminary effects of an advance care planning (ACP) programme "Have a Say" for persons with early stage dementia (PWEDs) and their family caregivers in the community. A quasi-experimental pretest-posttest study with a control group with repeated blinded outcome assessment will be conducted.
Individuals who have a clinical diagnosis of any form of dementia at the early stage or have a Global Deterioration Score (GDS) 3 or 4 will be eligible to this study. Participated elderly community centres will be assigned to intervention group and control group at 1:1 ratio. Staff members from centres assigned to intervention group will be trained as ACP facilitators and conduct the ACP intervention. Participants in the experimental group will receive a 3-session ACP programme. It includes an educational component, guided reflection and ACP discussion through a series of group-based activity and dyadic discussion delivered by trained ACP facilitator and guided by an ACP booklet. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion led by ACP facilitators and guided by an ACP booklet. Individuals assigned to the control group will receive attention-control health talks related to ageing. The feasibility of the trial design (in terms of subject recruitment and retention rate) and study instruments (in terms of data completness), and acceptability of intervention procedures (in terms of completion rate and satisfaction score) will be assessed.
As a process evaluation, a group of informants comprised of ACP facilitators and dyads of participants will be conveniently sampled and recruited for an semi-structured individual interview after receiving the intervention. Their experiences of participating in "Have a Say" programme as an ACP facilitator and participants will be explored. Qualitative data will be collected until data saturation. All verbatim will be transcribed and analyzed through qualitative content analysis. The results of this qualitative evaluation will enable us to understand the strengths and weaknesses of this ACP programme during implementation and give us insight about the mechanisms of impact and contextual factors affecting the intervention implementation, sustainability, and outcomes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kowloon, Hong Kong
- Hong Kong Family Welfare Society Kowloon City Centre for Active Ageing
-
Kowloon, Hong Kong
- Hong Kong Sheng Kung Hui Chuk Yuen Canon Martin District Elderly Community Centre
-
Kowloon, Hong Kong
- Hong Kong Sheng Kung Hui Lok Man Alice Kwok Integrated Service Centre
-
Kowloon, Hong Kong
- Yang Memorial Methodist Social Service Choi Hung Community Centre for Senior Citizens
-
Yuen Long, Hong Kong
- Mrs. Wong Tung Yuen District Elderly Community Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- being Chinese,
- being a Cantonese speaker,
- having a formal diagnosis of early stage dementia,
- having a Global Deterioration Scale score 3-4,
- having a designated family caregiver in direct contact.
Exclusion Criteria:
- non-communicable,
- mentally incompetent,
- received an ACP intervention,
- have previously signed an advance directive,
- have other life-limiting chronic illnesses.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Attention control
Dyads of participants in the control group will receive 3-session health talks.
One hour for each session, and once weekly.
The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health.
This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
|
Dyads of participants in the control group will receive 3-session health talks.
One hour for each session, and once weekly.
The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health.
This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
|
|
Experimental: Advance care planning programme
It is a theory-driven advance care planning programme specifically designed for PWEDs and their family caregivers.
The intervention is underpinned by the Bandura's self-efficacy model.
Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet.
It is composed of 1 group-based sessions and 2 dyadic discussions.
One hour for each session, and once weekly.
Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options.
Their values and care preferences on future care will be elicited in a consistent manner.
They will be supported to have an individualized ACP discussion.
By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
|
It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers.
The intervention is underpinned by the Bandura's self-efficacy model.
Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet.
It is composed of 1 group-based sessions and 2 dyadic discussions.
One hour for each session, and once weekly.
Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options.
Their values and care preferences on future care will be elicited in a consistent manner.
They will be supported to have an individualized ACP discussion.
By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in advance care planning engagement
Time Frame: Baseline, immediately after the intervention, 1 month and 3 months follow up
|
The behavior change process in ACP behaviours is measured using a 9-item ACP engagement survey.
It covers two sub-scales, self-efficacy and readiness, of ACP engagement.
Each item is rated on a 5-point likert scale.
The higher score means the higher level of engagement for the ACP behaviour.
|
Baseline, immediately after the intervention, 1 month and 3 months follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in dyadic concordance of end-of-life care preferences
Time Frame: Baseline, immediately after the intervention, 1 month and 3 months follow up
|
The dyadic concordance on end-of-life care preferences is measured by a modified Life Support Preferences Questionnaire (LSPQ).
Dyads of participants are invited to answer individually, simultaneously but separately on two hypothetical scenarios, one featured the prospect of developing into advance stage of dementia, and another scenario featured the prospect of developing into an irreversible vegetative stage.
PWEDs or persons with MCI are asked to consider themselves in each scenario and indicate their preference for receiving three discrete life-sustaining medical treatments (cardio-pulmonary resuscitation, mechanical ventilation and tube feeding) in each of the two scenarios using a 3 point Likert Scale (want to attempt, refuse or not sure).
The dyadic congruence is determined based on whether both of them choose the same option for end-of-life treatments and care goals for the two scenarios.
Score ranges from 0-8.
A higher score means a higher level of dyadic concordance.
|
Baseline, immediately after the intervention, 1 month and 3 months follow up
|
|
Depression
Time Frame: Baseline, immediately after the intervention, 1 month and 3 months follow up
|
The level of depression of PWEDs or persons with MCI is measured by the 19-item Cornell Scale for Depression in Dementia (CSDD).
It is to evaluate any adverse outcome posed by the intervention on them.
The score ranges from 0-38.
A cutoff point of nine or more indicating a depressive disorder, and a higher score means a higher depression level.
|
Baseline, immediately after the intervention, 1 month and 3 months follow up
|
|
Caregivers' stress
Time Frame: Baseline, immediately after the intervention, 1 month and 3 months follow up
|
Caregivers' stress is measured by the 12-item Zarit Caregiver Burden Interview.
It is to evaluate any adverse outcome posed by the intervention on family caregivers.
Score ranges from 0-48.
A higher score means a higher level of caregiver burden.
|
Baseline, immediately after the intervention, 1 month and 3 months follow up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subject recruitment rate
Time Frame: Baseline
|
The proportion of subjects referred by the centres who were eligible and consented to join the trial
|
Baseline
|
|
Subject attrition rate
Time Frame: Immediately after the intervention, 1 month and 3 months follow up
|
The proportion of subjects consented to the trial and dropout
|
Immediately after the intervention, 1 month and 3 months follow up
|
|
Completion rate
Time Frame: Immediately after the intervention
|
The proportion of subjects completed at least 2 sessions of the intervention out of 3.
|
Immediately after the intervention
|
|
Satisfaction score
Time Frame: Immediately after the intervention
|
Participants from the intervention group will be asked to complete a 5-item satisfaction questionnaire to provide ratings on the content, timing, and duration of the intervention; the usefulness of the information provided; and the performance of the ACP facilitators.
The items are rated on a 5-point Likert scale (5= totally agree; 1= totally disagree), with a higher total score indicating greater satisfaction with the intervention
|
Immediately after the intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chi Yan Cheryl Yeung, MN, Chinese University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIRCP R6303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
Saglik Bilimleri UniversitesiAnkara UniversityRecruitingAmnestic Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderTurkey
-
Masaryk UniversityRecruitingMild Cognitive Impairment (MCI) Amnestic | Lewy Body Disease With Mild Cognitive Impairment | Parkinson's Disease With Mild Cognitive ImpairmentCzechia
-
High Point UniversityWake Forest University Health Sciences; Hebrew SeniorLifeRecruitingMild Cognitive Impairment (MCI)United States
-
Azienda Ospedaliera SS. Antonio e Biagio e Cesare...Dr. Schär AG / SPARecruitingMild Cognitive Impairment (MCI)Italy
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Çankırı Karatekin UniversityCompletedMild Cognitive Impairment (MCI)Turkey (Türkiye)
-
University of AlbertaCompleted
-
Friedhelm HummelThe Novartis Foundation; Wyss Center for Bio and Neuroengineering; Clinique Romande... and other collaboratorsCompletedMild Cognitive Impairment (MCI)Switzerland
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)TerminatedAmnestic Mild Cognitive ImpairmentUnited States
Clinical Trials on ACP programme "Have a Say"
-
Hong Kong Metropolitan UniversityChinese University of Hong Kong; Food and Health Bureau, Hong KongCompletedMild Cognitive Impairment | Dementia MildHong Kong
-
Hong Kong Metropolitan UniversityChinese University of Hong KongCompleted
-
End-of-Life Research GroupCompletedElderly Care | Advance Care Planning | Nursing HomeBelgium
-
ACADIA Pharmaceuticals Inc.TerminatedOsteoarthritis PainUnited States
-
ACADIA Pharmaceuticals Inc.CompletedAcute Postoperative Pain | BunionectomyUnited States
-
Istanbul Aydın UniversityCompleted
-
Violeta Pajero OteroHospital Universitario 12 de Octubre; Puerta de Hierro University Hospital; University... and other collaboratorsCompletedBreast Cancer Lymphedema | Shoulder InjurySpain
-
The University of Hong KongCompleted
-
University of MalagaFundación Pública Andaluza para la Investigación de Málaga en Biomedicina...Completed
-
Maastricht University Medical CenterNationaal Fonds tegen KankerRecruitingBreast Cancer | Breast NeoplasmsNetherlands